THJ-2201: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
Line 1: Line 1:
'''THJ-2201''' is a synthetic cannabinoid that is the indazole analogue of AM-2201. It was first identified in illegal herbal products in Japan in 2013. It is presumed to be a potent agonist of the CB1 receptor, although it is unclear whether it is selective for this target. THJ-2201 is an Anlage II controlled substance in Germany as of May 2015. It is also banned in Sweden.
== THJ-2201 ==


==Chemistry==
[[File:THJ-2201.svg|thumb|right|Chemical structure of THJ-2201]]
THJ-2201 is a synthetic cannabinoid that is the indazole analogue of AM-2201. It is structurally related to other synthetic cannabinoids including AM-2201, AM-2233, and AB-PINACA. The systematic name of THJ-2201 is naphthalen-1-yl(1-(5-fluoropentyl)-1H-indazol-3-yl)-methanone.


==Pharmacology==
'''THJ-2201''' is a synthetic cannabinoid that has been used in scientific research and is often found in [[designer drugs]]. It is a potent agonist of the [[cannabinoid receptor]]s, which are part of the [[endocannabinoid system]] in the human body. THJ-2201 is structurally related to other synthetic cannabinoids such as [[JWH-018]] and [[AM-2201]].
THJ-2201 is presumed to be a potent agonist of the CB1 receptor, although it is unclear whether it is selective for this target. Synthetic cannabinoids such as THJ-2201 are often used in research to study the endocannabinoid system.


==Legal status==
=== Chemical Properties ===
THJ-2201 is an Anlage II controlled substance in Germany as of May 2015. It is also banned in Sweden. The legal status of THJ-2201 in other countries is unclear, but it may be controlled under analogue laws in countries such as the United States.
THJ-2201 is classified as an indazole-based synthetic cannabinoid. Its chemical structure is similar to that of AM-2201, with the primary difference being the substitution of an indazole core for the indole core found in AM-2201. This modification is believed to affect the binding affinity and selectivity of the compound for cannabinoid receptors.


==See also==
=== Pharmacology ===
* [[AM-2201]]
THJ-2201 acts as a full agonist at the [[CB1 receptor|CB1]] and [[CB2 receptor|CB2]] cannabinoid receptors. These receptors are part of the [[G protein-coupled receptor]] family and are involved in a variety of physiological processes including pain sensation, mood regulation, and appetite.
* [[AM-2233]]
 
* [[AB-PINACA]]
The effects of THJ-2201 are similar to those of other synthetic cannabinoids, which can include euphoria, altered perception, and relaxation. However, synthetic cannabinoids can also cause adverse effects such as anxiety, paranoia, and in some cases, severe health complications.
 
=== Legal Status ===
Due to its potential for abuse and lack of medical use, THJ-2201 is classified as a controlled substance in many countries. The legal status of synthetic cannabinoids can vary widely, with some jurisdictions banning specific compounds while others have broader legislation targeting entire classes of substances.
 
=== Health Risks ===
The use of THJ-2201, like other synthetic cannabinoids, is associated with significant health risks. These can include [[tachycardia]], [[hypertension]], [[hallucinations]], and [[seizures]]. The variability in potency and purity of synthetic cannabinoid products further increases the risk of adverse effects.
 
== Related Pages ==
* [[Synthetic cannabinoids]]
* [[Synthetic cannabinoids]]
* [[CB1 receptor]]
* [[Cannabinoid receptor]]
* [[Endocannabinoid system]]
* [[Designer drugs]]


[[Category:Synthetic cannabinoids]]
[[Category:Synthetic cannabinoids]]
[[Category:Indazoles]]
[[Category:Designer drugs]]
[[Category:Designer drugs]]
[[Category:Controlled substances]]
{{stub}}

Latest revision as of 04:02, 13 February 2025

THJ-2201[edit]

Chemical structure of THJ-2201

THJ-2201 is a synthetic cannabinoid that has been used in scientific research and is often found in designer drugs. It is a potent agonist of the cannabinoid receptors, which are part of the endocannabinoid system in the human body. THJ-2201 is structurally related to other synthetic cannabinoids such as JWH-018 and AM-2201.

Chemical Properties[edit]

THJ-2201 is classified as an indazole-based synthetic cannabinoid. Its chemical structure is similar to that of AM-2201, with the primary difference being the substitution of an indazole core for the indole core found in AM-2201. This modification is believed to affect the binding affinity and selectivity of the compound for cannabinoid receptors.

Pharmacology[edit]

THJ-2201 acts as a full agonist at the CB1 and CB2 cannabinoid receptors. These receptors are part of the G protein-coupled receptor family and are involved in a variety of physiological processes including pain sensation, mood regulation, and appetite.

The effects of THJ-2201 are similar to those of other synthetic cannabinoids, which can include euphoria, altered perception, and relaxation. However, synthetic cannabinoids can also cause adverse effects such as anxiety, paranoia, and in some cases, severe health complications.

Legal Status[edit]

Due to its potential for abuse and lack of medical use, THJ-2201 is classified as a controlled substance in many countries. The legal status of synthetic cannabinoids can vary widely, with some jurisdictions banning specific compounds while others have broader legislation targeting entire classes of substances.

Health Risks[edit]

The use of THJ-2201, like other synthetic cannabinoids, is associated with significant health risks. These can include tachycardia, hypertension, hallucinations, and seizures. The variability in potency and purity of synthetic cannabinoid products further increases the risk of adverse effects.

Related Pages[edit]